BACKGROUND AND PURPOSE: Many compounds liberating NO (NO donors) have been used as therapeutic agents. Here we test two ruthenium nitrosyls, which release NO when activated by biological reducing agents, for their effects in vitro and in vivo against Trypanosoma cruzi, the agent responsible for the American trypanosomiasis (Chagas' disease). EXPERIMENTAL APPROACH: Ruthenium NO donors were incubated with a partially drug-resistant strain of T. cruzi and the anti-proliferative and trypanocidal activities evaluated. In a mouse model of acute Chagas' disease, trypanocidal activity was evaluated by measuring parasitemia, survival rate of infected mice and elimination of amastigotes in myocardial tissue. KEY RESULTS: In vitro, the observed anti-proliferative and trypanocidal activities of trans-[Ru(NO)(NH(3))(4)isn](BF(4))(3) and trans-[Ru(NO)(NH(3))(4)imN](BF(4))(3) were due to NO liberated upon reduction of these nitrosyls. Ru(NO)isn had a lower IC(50 epi) (67 microM) than the NO donor, sodium nitroprusside (IC(50 epi)=244 microM) and Ru(NO)imN (IC(50 try)=52 microM) was more potent than gentian violet (IC(50 try)=536 microM), currently used in the treatment of blood. Both ruthenium nitrosyls eliminated, in vivo, extracellular as well as intracellular forms of T. cruzi in the bloodstream and myocardial tissue and allowed survival of up to 80% of infected mice at a dose (100 nmol kg(-1) day(-1)) much lower than the optimal dose for benznidazole (385 micromol kg(-1) day(-1)). CONCLUSIONS AND IMPLICATIONS: Our data strongly suggest that NO liberated is responsible for the anti-proliferative and trypanocidal activities of the ruthenium NO donors and that these compounds are promising leads for novel and effective anti-parasitic drugs.
BACKGROUND AND PURPOSE: Many compounds liberating NO (NO donors) have been used as therapeutic agents. Here we test two ruthenium nitrosyls, which release NO when activated by biological reducing agents, for their effects in vitro and in vivo against Trypanosoma cruzi, the agent responsible for the American trypanosomiasis (Chagas' disease). EXPERIMENTAL APPROACH: Ruthenium NO donors were incubated with a partially drug-resistant strain of T. cruzi and the anti-proliferative and trypanocidal activities evaluated. In a mouse model of acute Chagas' disease, trypanocidal activity was evaluated by measuring parasitemia, survival rate of infected mice and elimination of amastigotes in myocardial tissue. KEY RESULTS: In vitro, the observed anti-proliferative and trypanocidal activities of trans-[Ru(NO)(NH(3))(4)isn](BF(4))(3) and trans-[Ru(NO)(NH(3))(4)imN](BF(4))(3) were due to NO liberated upon reduction of these nitrosyls. Ru(NO)isn had a lower IC(50 epi) (67 microM) than the NO donor, sodium nitroprusside (IC(50 epi)=244 microM) and Ru(NO)imN (IC(50 try)=52 microM) was more potent than gentian violet (IC(50 try)=536 microM), currently used in the treatment of blood. Both ruthenium nitrosyls eliminated, in vivo, extracellular as well as intracellular forms of T. cruzi in the bloodstream and myocardial tissue and allowed survival of up to 80% of infected mice at a dose (100 nmol kg(-1) day(-1)) much lower than the optimal dose for benznidazole (385 micromol kg(-1) day(-1)). CONCLUSIONS AND IMPLICATIONS: Our data strongly suggest that NO liberated is responsible for the anti-proliferative and trypanocidal activities of the ruthenium NO donors and that these compounds are promising leads for novel and effective anti-parasitic drugs.
Authors: Simone da S. S. Borges; Celso U. Davanzo; Eduardo E. Castellano; Julio Z-Schpector; Sebastião C. Silva; Douglas W. Franco Journal: Inorg Chem Date: 1998-06-01 Impact factor: 5.165
Authors: Alisson L Matsuo; Luis S Silva; Ana C Torrecilhas; Bruno S Pascoalino; Thiago C Ramos; Elaine G Rodrigues; Sergio Schenkman; Antonio C F Caires; Luiz R Travassos Journal: Antimicrob Agents Chemother Date: 2010-05-17 Impact factor: 5.191
Authors: Wander Rogério Pavanelli; Jean Jerley Nogueira da Silva; Carolina Panis; Thiago Mattar Cunha; Ivete Conchon Costa; Maria Claudia Noronha Dutra de Menezes; Francisco José de Abreu Oliveira; Luiz Gonzaga de França Lopes; Rubens Cecchini; Fernando de Queiroz Cunha; Maria Angélica Ehara Watanabe; Eiko Nakagawa Itano Journal: Mycopathologia Date: 2011-03-25 Impact factor: 2.574
Authors: Paulo M M Guedes; Fabiana S Oliveira; Fredy R S Gutierrez; Grace Kelly da Silva; Gerson Jhonatan Rodrigues; Lusiane Maria Bendhack; Douglas W Franco; Maria A Do Valle Matta; Dario S Zamboni; Roberto Santana da Silva; João Santana Silva Journal: Br J Pharmacol Date: 2010-01-27 Impact factor: 8.739
Authors: Tanira M Bastos; Marília I F Barbosa; Monize M da Silva; José W da C Júnior; Cássio S Meira; Elisalva T Guimaraes; Javier Ellena; Diogo R M Moreira; Alzir A Batista; Milena B P Soares Journal: Antimicrob Agents Chemother Date: 2014-08-04 Impact factor: 5.191
Authors: Jean Jerley N Silva; Wander R Pavanelli; José Clayston M Pereira; João S Silva; Douglas W Franco Journal: Antimicrob Agents Chemother Date: 2009-07-06 Impact factor: 5.191
Authors: Zumira A Carneiro; Pedro I da S Maia; Renata Sesti-Costa; Carla D Lopes; Tatiana A Pereira; Cristiane M Milanezi; Marcelo A Pereira da Silva; Renata F V Lopez; João S Silva; Victor M Deflon Journal: PLoS Negl Trop Dis Date: 2014-05-08